NGY-091 / Nirogy - LARVOL DELTA

Therapeutic efficacy of NGY-091 against triple negative breast cancer is mediated by direct cell killing and activation of antitumor immunity (SABCS 2022) - "These findings indicate the direct effect of NGY-091 on immune cell and validate the in vivo observations in 4T1 tumors. Therefore, NGY-091 intervenes two key hallmarks of cancer – metabolism and immunity and provides a novel avenue to therapeutically target aggressive breast cancer."

Clinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CD8 • MCT1

Lactate Modulation in Cancer and Immune Cells is Associated with Antitumor Efficacy of dual MCT1/MCT4 Inhibitor NGY-091 (SITC 2022) - "We examined lactate import by MDSCs and Tregs, as these cells are known to utilize lactate as a source of energy, and found that NGY-091 strongly decreased lactate import in these cells. Conclusions NGY-091 modulates lactate transport to induce direct cytotoxicity in cancer and activate robust antitumor immunity."

Clinical • Oncology • CD4 • CD8

Novel Pharmacological Approach to Induce Direct Killing of Cancer and Activate Antitumor Immunity via Inhibition of Monocarboxylate Transporters (SITC 2022) - "Importantly, NGY-091 significantly reduced the growth and functionality of Treg and MDSCs. Conclusions Therefore, NGY-091 intervenes with two key hallmarks of cancer – metabolism and immunity and has a strong therapeutic utility in cancer treatment."

IO biomarker • Oncology • CD4 • CD8

Cellular transporters as novel metabolic immune checkpoints: NGY-091, a small molecule dual MCT1/4 inhibitor for immuno oncology (AACR-NCI-EORTC 2022) - "These findings indicate the direct effect of NGY-091 on immune cells and validate the in vivo observations in 4T1 tumors. Therefore, NGY-091 intervenes with two key hallmarks of cancer, metabolism and immunity and provides a novel modality to therapeutically target cancer."

IO biomarker • Oncology • CD4 • CD8 • MCT1

NGY-B is a novel inhibitor of MCT transporters blocking lactate and glucose metabolisms (AACR 2022) - "Seahorse and U-13C-glucose tracing analysis demonstrated NGY-B treatment modulates glycolysis and oxidative phosphorylation consistent with the lactate measurement data. Therefore, NGY-B is a novel inhibitor of MCT1/4 while also exhibiting inhibition of mitochondrial respiration."

Oncology • MCT1

Efficacy of a small molecule MCT1 and MCT4 transporter inhibitor in cancer (AACR 2022) - "Furthermore, we demonstrated the direct tumor cell killing effect of NGY-B in multiple human CDX and PDX models. Therefore, NGY-B intervenes two key hallmarks of cancer - tumor metabolism and anti-tumor immunity, and provides a novel modality to therapeutically target cancer."

Clinical • Hematological Malignancies • Oncology • IDH1

[VIRTUAL] Dual MCT1/4 inhibition promotes anti-tumor immunity in triple-negative breast cancer (AACR 2021) - "Despite the recent FDA approval of Abraxane (nab-paclitaxel) and Atezolizumab (anti-PD-L1) for a subset of Triple-Negative Breast Cancer (TNBC) patients, there remains an unmet need to develop novel therapeutic strategies to effectively combat this disease. Therefore, such a broader effect on multiple immune cells by NGY-B leads to overall immune activation in the TME. Our pre-clinical work shows that NGY-B intervenes two key hallmarks of caner; metabolism and immunity, providing us a novel therapeutic modality to combat TNBC."

IO biomarker • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • MCT1

[VIRTUAL] A novel treatment approach for melanoma by dually targeting MCT1 and MCT4 lactate transporters (AACR 2021) - "Supporting this premise, we also found that NGY-B treated cells showed a decrease in PD-L1, B7-H3, and B7-H4 expression. Overall, our results indicate that NGY-B inhibits melanoma by targeting metabolic symbiosis and activating antitumor immune response mechanisms."

IO biomarker • Melanoma • Oncology • Solid Tumor • CD276 • HK2 • PD-L1 • PDPK1 • PHGDH

Nirogy Therapeutics to Present at AACR Annual Meeting 2021 (GlobeNewswire) - “Nirogy Therapeutics…announced that the company will present two e-posters at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held on April 10-15, 2021 and May 17-21, 2021. Nirogy will highlight preliminary data that shows that NGY-B, the company’s first-in-class, orally bioavailable small molecule inhibitor, intervenes in two key hallmarks of cancer, metabolism and immunity, providing a potential novel therapeutic modality to combat triple-negative breast cancer (TNBC). Nirogy will also highlight preclinical data that demonstrate the potential of NGY-B to inhibit melanoma by targeting metabolic symbiosis and activating antitumor immune response mechanisms.”

Preclinical • Breast Cancer • Melanoma • Oncology • Skin Cancer • Solid Tumor • Triple Negative Breast Cancer